Lawrence Shulman, MD: The Global Impact of Biosimilar Trastuzumab
January 7th 2019Lawrence Shulman, MD, deputy director for clinical services and director of the Center for Global Cancer Medicine at the Abramson Cancer Center at the University of Pennsylvania, discusses the global impact of biosimilar trastuzumab.
Lawrence Shulman, MD: Preparing for Biosimilar Trastuzumab
January 2nd 2019Lawrence Shulman, MD, deputy director for clinical services and director of the Center for Global Cancer Medicine at the Abramson Cancer Center at the University of Pennsylvania, discusses the arrival of biosimilar trastuzumab.
Ha Kung Wong: FDA and FTC Cooperation to Address Anticompetitive Behavior
September 4th 2018Ha Kung Wong, JD, partner at Fitzpatrick, Cella, Harper and Scinto, discusses how the FDA and Federal Trade Commission (FTC) might work together to address anticompetitive behavior in the biosimilars marketplace.